<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00358124</url>
  </required_header>
  <id_info>
    <org_study_id>HOE901_4014</org_study_id>
    <nct_id>NCT00358124</nct_id>
  </id_info>
  <brief_title>Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To compare the glycemic control, as measured by HbA1C, between insulin glargine and
      rosiglitazone add-on therapies in patients who fail oral combination of a sulfonylurea and
      metformin
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date>June 2002</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy variable was the change in HbA1C from baseline to the end of therapy.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Other efficacy variables were the change from baseline in FPG, serum lipids and weight.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy parameters were: a mean change from baseline in FPG</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in fasting insulin/C-peptide levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in lipid levels (total cholesterol, HDL, LDL, TG, free fatty acids)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline for bodyweight.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life was compared between the baseline visit and the follow-up assessments</measure>
  </secondary_outcome>
  <enrollment>220</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Diagnosis of type 2 diabetes mellitus for at least one year;

          -  Continuous treatment with at least half maximally labeled dose of a sulfonylurea and
             at least 1000 mg metformin daily for at least three months ;

          -  Glycated hemoglobin between 7.5 and 11 % units, inclusive;

          -  Willingness to accept, and ability to inject insulin glargine therapy

        EXCLUSION CRITERIA:

          -  Stroke, MI, coronary artery bypass graft, percutaneous transluminal coronary
             angioplasty or angina pectoris within the last 12 months;

          -  Congestive heart failure requiring pharmacological treatment;

          -  Serum creatinine &gt; 1.5 mg/dl for males, or &gt; 1.4 mg/dl for females;

          -  Acute or chronic metabolic acidosis, including diabetic ketoacidosis;

          -  Planned radiological examinations requiring administration of contrasting agents;

          -  Clinical evidence of active liver disease, or serum ALT 2.5 times the upper limit of
             the normal range;

          -  History of hypoglycemia unawareness;

          -  Pregnancy or lactation;

          -  Failure to use adequate contraception (women of current reproductive potential only);

          -  Known hypersensitivity to insulin glargine, rosiglitazone or any of the components of
             insulin glargine rosiglitazone;

          -  BMI &gt;25 kg/m2;

          -  Malignancy except basal cell carcinoma within the last five years;

          -  History of substance or alcohol abuse within last two years, or current addiction to
             substance or alcohol abuse;

          -  Any disease or condition that in the opinion of the investigator and/or sponsor may
             interfere with completion of the study;

          -  Incapability to comply with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Barch</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006 Mar;29(3):554-9.</citation>
    <PMID>16505505</PMID>
  </reference>
  <reference>
    <citation>Vinik AI, Zhang Q. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care. 2007 Apr;30(4):795-800. Epub 2007 Jan 26. Erratum in: Diabetes Care. 2007 Jun;30(6):1684.</citation>
    <PMID>17259481</PMID>
  </reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2006</study_first_submitted>
  <study_first_submitted_qc>July 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2006</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

